Vironika, LLC, secured a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop a small molecule inhibitor for Epstein-Barr Virus (EBV) lytic reactivation.
“We are thrilled to receive funding for the development of an inhibitor for EBV lytic reactivation, an important aspect in virus-dependent tumor formation,” says Baiwei Gu, Ph.D., Principal Investigator of this grant.
The grant will allow Vironika to follow up on initial screening for inhibitors of EBV lytic reactivation, and develop lead compounds that show great efficacy and specificity in biochemical, cellular and in vivo assays.
Vironika, LLC, is a privately held company founded in 2009 by Paul Lieberman, Ph.D. Dr. Lieberman is a full Professor at the Wistar Institute in Philadelphia.